SCHEMBL5885776

SCHEMBL5885776

Cc1cc(C#CCN(Cc2ccccc2)c2cccc(C#N)c2)ccc1C(=O)N1CC=CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.39
AR P10275 1/20 0.39
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
KMT2A Q03164 1/20 0.37
CCR5 P51681 1/20 0.37
KCNH2 Q12809 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
NR3C1 P04150 1/20 0.37
PTGES O14684 5/20 0.36
FFAR1 O14842 1/20 0.35
FAAH O00519 1/20 0.35
TMEM97 Q5BJF2 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
ACACB O00763 1/20 0.34
DCUN1D1 Q96GG9 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886153 0.91 AR (0.48) KDM1AARMEN1NPC1KMT2A
SCHEMBL5885782 0.86 PTPN1 (0.37) KMT2ACRHBPCRHR2PTGESACACB
SCHEMBL5886169 0.86 PPARG (0.38) FFAR1ACACB
Hydrochloric Acid SCHEMBL5885081 0.85 PTPN1 (0.37) KMT2ACRHBPCRHR2PTGESACACB
SCHEMBL5885457 0.85 MEN1 (0.43) KDM1AMEN1NPC1KMT2ACRHBP
SCHEMBL5885689 0.84 PTGES (0.40) MEN1NPC1KMT2ACRHBPCRHR2
SCHEMBL5885625 0.83 GRM5 (0.37) FFAR1
SCHEMBL5885627 0.82 PDK1 (0.40) KDM1AARPTGESACACB
SCHEMBL5885722 0.81 ELANE (0.41) ARACACB
SCHEMBL5885843 0.81 ACACB (0.41) KDM1AARNPC1CCR5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7005437-B2 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2006-02-28 US disclosed
EP-1404648-A1 AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-04-07 EP disclosed
WO-2003101942-A1 AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-11 WO disclosed
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions F2, F12, F3 KDM1A 2628/4885AR 1214/4885MEN1 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.